Mechanisms of the graft-versus-leukemia reaction

Stem Cells

Volumn 15, Issue 4, 1997, Pages 248-258

  Barrett, A J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Bone marrow transplantation; Graft versus host disease; Graft versus leukemia; Immunogenicity; Leukemia; T cells

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; BONE MARROW TRANSPLANTATION; CYTOPATHOGENIC EFFECT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOGENICITY; LEUKEMIA; PATHOPHYSIOLOGY; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0030871850     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.150248     Document Type: Review

References (106)

1. Barrett AJ, Malkovska V. The graft-versus-leukemia effect. Curr Opin Oncol 1996;8:89-95.
2. Kourilsky P, Claverie JM. MHC-antigen interaction: what does the T cell receptor see? Adv Immunol 1989;45:107-115.
3. Perreault C, Decary F, Brochu S et al. Minor histocompatibility antigens. Blood 1990;76:1269-1277.
4. Knuutila S. Lineage specificity in haematological neoplasms. Br J Haematol 1997;96:2-11.
5. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995;85:1151-1168.
6. + subpopulations. Blood 1995;86:2906-2912.
7. Lapidot T, Sirad C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-646.
8. Dermime S, Mavroudis DA, Jiang YZ et al. Immune escape from a graft versus leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;19:989-999.
9. Barnes DWH, Loutit JF. Treatment of murine leukemia with x-rays and homologous bone marrow. Br Med J 1956;2:626-627.
10. Truitt RL, Johnson BD. Review: principles of graft versus leukemia reactivity. Biol Blood Marrow Transplant 1995;1:61-68.
11. Malkovska V, Cigel F, Storer BE. Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumor immunity. Clin Exp Immunol 1994;96:158-165.
12. Weichold FF, Jiang Y-Z, Dunn DF et al. Tumors of HLA-DRI expressing K562 cells in SCID mice are resistant to the antitumor effect of unprimed human lymphocytes. Blood 1996;88(suppl 1):677a.
13. + cytotoxic cells from patients with chronic phase (CP) CML: in vivo efficacy in SCID mice. Blood 1996;88(suppl 1):675a.
14. Findlay HW, Yeager AM, Fleming WH. Allogeneic peripheral blood mononuclear cells inhibit the growth of human acute lymphoblastic leukemia in BNX mice. Blood 1996;88(suppl 1):677a.
15. Van Rhee F, Kolb H-J. Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol 1995;2:423-429.
16. Korngold R, Sprent J. T cell subsets and graft versus host disease. Transplantation 1987;44:335-339.
17. O'Kunewick J, Kociban D, Machen L et al. Effect of selective donor T-cell depletion on the graft-versus-leukemia reaction in allogeneic marrow transplantation. Transplant Proc 1992;24:2998-3004.
18. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991;8:51-58.
19. + T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 1995;60:355.
20. + lymphocyte lines generated in vitro against chronic myelogenous leukemia. Exp Hematol 1995;23:1167-1172.
21. Oettel KR, Wesly OH, Albertini MR et al. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosomebearing (Ph1+ human leukemia lines can also recognize Ph1- cells from the same patient). Blood 1994;83:3390-3402.
22. Faber LM, van Luxemburg-Heijs SA, Willemz R et al. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992;176:1283-1289.
23. van Lochem E, de Gast B, Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992;10:181-183.
24. + cytotoxic T-lymphocyte clones from a patient with severe graft versus host disease after allogeneic bone marrow transplantation: implications for graft versus leukemia reactivity. Blood 1995;86:2821-2828.
25. Hoffmann T, Theobald M, Bunjes D et al. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells. Bone Marrow Transplant 1993;12:l-8.
26. Jiang YZ, Kanfer EJ, MacDonald D et al. Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T-lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant 1991;8:253-258.
27. + cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 1994;57:82-87.
28. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86:4337-4343.
29. + cell content in donor bone marrow. Blood 1995;86(suppl 1):571a.
30. Verdonck LF, Dekker AW, de Gast GC et al. Allogeneic bone marrow transplantation with a fixed low number of T-cells in the marrow graft. Blood 1994;83:3090-3096.
31. Hercend T, Takvorian T, Nowill A et al. Characterization of natural killer cells with antileukemic activity following allogeneic bone marrow transplantation. Blood 1986;67:722-730.
32. Malnati MS, Peruzzi M, Parker KC et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 1995;267:1016-1018.
33. Kurago ZB, Smith KD, Lutz CT. NK cell recognition of MHC class I. J Immunol 1995;153:2631-2641.
34. Jiang YZ, Couriel D, Mavroudis D et al. MHC class II gene transfer reduces tumor cell susceptibility to natural killer cell mediated cytotoxicity. Immunology 1996;87:481-486.
35. Glass B, Uharek L, Zeis M et al. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol 1996;93:412-419.
36. Jiang YZ, Barrett AJ, Goldman JM et al. Association of natural killer cell immune recovery with a graft-vs.-leukemia effect independent of graft vs. host disease after allogeneic bone marrow transplantation. Ann Hematol 1997 (in press).
37. Mackinnon S, Hows JM, Goldman JM. Induction of in vitro graft-versus-host activity following bone marrow transplantation for chronic myeloid leukemia. Blood 1990;76:2037-2045.
38. Jiang YZ, Cullis JO, Kanfer EJ et al. T cell and NK cell mediated graft versus leukemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplantation 1993;11:133-138.
39. Pinet V, Malnati MS, Long EO. Two processing pathways for the MHC class II restricted presentation of exogenous influenza virus antigen. J Immunol 1994;152:4852-4860.
40. Nuchtern JG, Biddison WE, Klausner RD. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 1990;343:74-76.
41. Delain M, Tiberghien P, Racadot E et al. Variability of the alloreactive T-cell response to human leukemic blasts. Leukemia 1994;8:642-647.
42. Choudhury A, Gajewski JL, Liang JL et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia-chromosome positive chronic myelogenous leukemia. Blood 1997;89:1133-1142.
43. + T lymphocytes can exert cytotoxicity to CML cells processing and presenting exogenous antigen. Br J Hematol 1996;93:606-614.
44. Barrett AJ, Jiang YZ. Review: immune response to chronic myeloid leukemia. Bone Marrow Transplant 1992;9:305-311.
45. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
46. Van Rhee F, Feng L, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation: the case for giving donor leucocyte transfusions before the onset of hematological relapse. Blood 1994;83:3377-3383.
47. + cytotoxic T-cells induce apoptosis of APC. Eur J Immunol 1992;22:267-276.
48. + mediated cytotoxicity. J Immunol 1994;152:1127-1134.
49. Zychlinsky A, Zheng LM, Liu CC et al. Cytolytic lymphocytes induce both apoptosis and necrosis in target cells. J Immunol 1991;146:393-400.
50. + cytotoxic T lymphocytes. Human Immunol 1996;45:64.
51. + cytotoxic T cells. Proc Natl Acad Sci USA 1994;91:4185-4189.
52. Kagi D, Vignaux F, Ledermenn B et al. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-530.
53. Falkenburg JHF, Goselink HM, van der Harst D et al. Growth inhibition of clonogeneic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991;174:27-37.
54. Munker R, Lubbert M, Yonehara S et al. Expression of the fas antigen on primary human leukemia cells. Ann Hematol 1995;70:15-17.
55. Selleri C, Sato T, del Vecchio L et al. Involvement of Fasmediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukaemia. Blood 1997;89.
56. Zoumbos NC, Djeu JY, Young NS. Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol 1984;133:769-774.
57. Munker R, Koeffler P. In vitro action of tumor necrosis factor on myeloid leukemia cells. Blood 1987;69:1102-1108.
58. Naume B, Gately M, Espevik T. A comparative study of IL-12,IL-2 and IL-7 induced effectors on immunomagnetically purified CD56 NK cells. J Immunol 1992;148:2429-2436.
59. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today 1996;17:214-217.
60. Broxmeyer HE, Williams DE, Lu L et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986;136:4487-4495.
61. Niederwieser D, Aubock J, Troppmair J et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol 1988;140:2556-2564.
62. Matulonis UA, Dosiou C, Lamont C et al. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995;85:2507-2515.
63. Schultze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response. Blood Rev 1996;10:111-127.
64. Gribben J, Guinan E, Boussiotis Ke X-Y et al. Complete blockade of B7 family-mediated co-stimulation is necessary to induce human alloantigen specific anergy: a method to ameliorate graft versus host disease and extend the donor pool. Blood 1996;87:4887-4893.
65. Lowdell MW, Shamim F, Hamon M et al. VLA-6 (Cdw49f) is an important adhesion molecule in NK-mediated toxicity following autologous and allogeneic bone marrow transplantation. Exp Hematol 1995;23:1530-1534.
66. Goulmy E. Minor histocompatibility antigens and their role in transplantation. Transplant Rev 1988;2:29-53.
67. Van der Harst D, Goulmy E, Falkenberg JHF et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cell lines by cytotoxic T-cell clones. Blood 1994;83:1060-1066.
68. de Bueger M, Bakker A, van Rood JJ et al. Tissue distribution of minor histocompatibility antigens. J Immunol 1992;149:1788-1794.
69. Wang W, Meadowa LR, den Haan JMM et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995;269:1588-1590.
70. den Haan JMM, Sherman NE, Blokland E et al. Identification of a graft-versus-host disease-associated minor histocompatibility antigen. Science 1995;268:1476-1479.
71. Chen W, Chatta K, Rubin W et al. Polymorphic segments of CD45 can serve as targets for GVHD and GVL responses. Blood 1995;86(suppl 1):157a.
72. Malkovska V, Cigel F, Sondel P et al. Synthetic peptides derived from the CD19 protein bind to the class I HLA-A2.1. Blood 1995;86(suppl 1):157a.
73. Molldrem J, Dermime S, Parker K et al. Targeted T cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase-3 preferentially lyse human myeloid leukemia cells. Blood 1996;88:2450-2457.
74. + T lymphocytes recognize the fusion region of BCR/ABL hybrid protein present in chronic myelogenous leukemia. Blood 1995;86(suppl 1):158a.
75. Bocchia M, Korontsvit T, Xu Q et al. Specific human cellular immunity to bcr/abl oncogene-derived peptides. Blood 1996;87:3587-3592.
76. Pawelec G, Max H, Halder T et al. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 1996;88:2118-2124.
77. Greco G, Fruci D, Accapezzato D et al. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996;10:695-671.
78. ten Bosch GJA, Toornvliet AC, Friede T et al. Recognition of peptides corresponding to the joining region of p210 BCR-ABL protein by human T cells. Leukemia 1995;9:1344-1350.
79. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996;88:3522-3530.
80. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
81. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
82. Rettie JE, Gottleib D, Heslop H et al. Endogenously generated activated killer cells circulate after autologous and allogeneic bone marrow transplantation but not after chemotherapy. Blood 1989;73:1351-1358.
83. Collins RH Jr, Rogers ZR, Bennett M et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992;10:391-395.
84. Mehta J, Powles RL, Singhal S et al. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;16:133-138.
85. Tricot G, Vesole D, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-1198.
86. Verdonck LF, Lokhorst HM, Dekker AW et al. Graft-versus-myeloma effect in two cases. Lancet 1996;347:800-801.
87. Alyea EP, Schlossman RL, Canning C et al. CD8-depleted donor lymphocyte infusions mediate graft-versus-multiple myeloma effect. Blood 1996;88(suppl 1):258a.
88. Anasetti C, Hansen JA, Waldman TA. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994;84:1320-1327.
89. Herve P, Flesch M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor-α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992;79:3362-3368.
90. Fowler DH, Kurasawa K, Smith R et al. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994;84:3540-3549.
91. Krenger W, Ferrara JLM. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res 1996;15:50-73.
92. Blazar BR, Taylor PA, Linsley PS et al. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994;83:3815-3825.
93. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995;85:3302-3312.
94. Naparstek E, Or R, Nagler A et al. T-cell depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995;89:506-515.
95. Thiberghien P, Reynolds CW, Keller J et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994;84:1333-1341.
96. Gallot G, Hallet M, Gaschet J et al. Human HLA-specific T-cell clones with stable expression of a suicide gene: a possible tool to drive and control a graft-versus-host-graft-versus-leukemia reaction? Blood 1996;88:1098-1103.
97. Cavazzana-Calvo M, Stephan JL, Sarnacki S et al. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 1994;83:288-298.
98. Datta AR, Jiang YZ, Guimarães A et al. Distinct T cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994;14:517-524.
99. Mavroudis DA, Jiang YZ, Hensel N et al. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 1996;17:793-799.
100. Rencher SD, Houston JA, Lockey TD et al. Eliminating graft-versus-host potential from T cell immunotherapeutic populations. Bone Marrow Transplant 1996;18:415-420.
101. Mavroudis DA, Dermime S, Jiang YZ et al. Selective immunodepletion between HLA matched siblings that reduces the risk for GVHD and preserves reactivity against the leukemia and Epstein-Barr virus. Blood 1996;88(suppl 1):254a.
102. Jiang YZ, Mavroudis DA, Dermime S et al. Limited usage of T cell receptor (TCR Vβ T cells responding to chronic myelogenous leukemia (CML): implications for positively selecting and specifically enhancing the graft versus leukemia effect. Bone Marrow Transplant 1997 (in press).
103. Falkenberg JHF, Faber LM, van der Elshout M et al. Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J Immunother 1993;14:305-309.
104. Kwak L, Taib D, Duffey PL et al. Transfer of myeloma idio-type-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016-1020.
105. + lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein PML/RARa present in acute promyelocytic cells. Blood 1993;81:1369-1375.
106. Hoshino T, Jiang YZ, Dunn D et al. Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor: implications for tumor vaccination. Hum Gene Ther 1997 (in press).